Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • Wednesday
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial HypertensionBusiness Wire • Wednesday
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase AuthorizationBusiness Wire • 10/22/26
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026Business Wire • 10/21/26
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production FacilityBusiness Wire • 10/20/26
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPDBusiness Wire • 10/19/26
Liquidia shares surge 25% as settlement ends United Therapeutics litigationProactive Investors • 10/14/26
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%24/7 Wall Street • 10/14/26
Liquidia And United Therapeutics Settle; But Only One Stock SkyrocketedInvestors Business Daily • 10/14/26
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%Zacks Investment Research • 10/01/26
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For ThursdayBenzinga • 10/01/26
United Therapeutics Stock Rises Following Federal Court Patent Victory Over LiquidiaBenzinga • 10/01/26
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?Zacks Investment Research • 10/01/26
United Therapeutics Corporation Prevails in Patent Litigation Against LiquidiaBusiness Wire • 09/30/26
United Just Pulled The Ultimate Bull Move, As Its Chief Rival CollapsedInvestors Business Daily • 09/30/26
United Therapeutics Corporation (UTHR) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum TranscriptSeeking Alpha • 09/23/26